Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-23T07:55:18.502Z Has data issue: false hasContentIssue false
  • English
  • Français

Nicotinic Acid Modified Lysergic Acid Diethylamide Psychosis

Published online by Cambridge University Press:  08 February 2018

N. Agnew  and
A. Hoffer
Get access Rights & Permissions [Opens in a new window]

Extract

Theoretical models ranging from neurological to analytical have been introduced in the hope of providing new insights into psychopathology. The flesh and blood model is of more recent origin in this field. The experimental or model psychosis results from giving “normals” drugs which bring about a psychotic-like experience for a few hours. As is the case with theoretical models, the flesh and blood models are not accurate representations of the naturally occurring psychosis. In fact, the variability manifest in most naturally occurring psychoses makes the existence of an accurate model impossible. A model, whether carefully planned and developed or accidentally discovered, is useful to the extent that it assists us in better understanding the naturally occurring process it approximates. It is useful if it enables us to set up and test hypotheses which contribute additional knowledge about disease aetiology, mechanisms, or treatment. The model psychosis to be studied in this paper is that produced by lysergic acid diethylamide (LSD).

Type
Original Articles
Information
Journal of Mental Science , Volume 101 , Issue 422 , January 1955 , pp. 12 - 27
Copyright
Copyright © Royal College of Psychiatrists, 1955 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. DeShon, H. J., Rinkel, M., and Solomon, H. C., “Mental changes experimentally produced by LSD”, Psychiatric Quarterly, 1952, 26, 33.Google Scholar
2. Rinkel, M., DeShon, H. J., Hyde, R. W., and Solomon, H. C., “Experimental schizophrenia-like symptoms”, Amer. J. Psychiat., 1952, 108, 572.Google Scholar
3. Busch, A. K., and Johnson, W. C., “LSD 25 as an aid in psychotherapy (preliminary report of a new drug)”, Dis. Nerv. System, 1950, 11, 241.Google Scholar
4. Savage, C., “Lysergic acid diethylamide (LSD-25)—a clinical psychological study”. Amer. J. Psychiat., 1952, 108, 896.Google Scholar
5. Mayer-Gross, W., McAdam, W., and Walker, J. W., “Further observations on the effects of lysergic acid diethylamide”, J. Ment. Sci., 1953, 99, 804.Google Scholar
6. Idem , “Lysergsäure diäthylamid und Kohlenhydratstoffwechsel”, Der. Nervenartz, 1952, 1, 30.Google Scholar
7. Schueler, F. W., “The effect of succinate in mescaline hallucination”, J. Lab. and Clin. Med., 1948, 33, 1297.Google Scholar
8. Iancovescu, N., and Stroescu, G., “Psychoses due to pellagra and their therapy with nicotinic acid”, Rev. San. Mil. Bucuresti., 1939, 38, 769.Google Scholar
9. Joliffe, N., Bowman, K. M., Rosenblum, L. A., and Fein, H. O., “Nicotinic acid deficiency encephalopathy”, J.A.M.A., 1940, 114, 307.Google Scholar
10. Cleckley, H. M., Sydenstricker, V. P., and Geeslin, L. E., “Nicotinic acid in the treatment of atypical psychotic states”, J.A.M.A., 1939, 112, 2107.Google Scholar
11. Washburne, A. C., “Nicotinic acid in the treatment of certain depressed states: a preliminary report”, Annals of Internal Medicine, 1950, 52, 261.Google Scholar
12. Sherrill, D., “Nicotinic acid in the treatment of certain depressed states”, The Journal of the Bowman Gray School of Medicine, 1950, 8, 137.Google Scholar
13. Gould, J., “Treatment of delirium, psychoses and coma due to drugs”, Lancet, 1953, 570. 21 March. Google Scholar
14. Sydenstricker, V. P., and Cleckley, H. M., “The effect of nicotinic acid in stupor, lethargy and various other psychiatric disorders”, Amer. J. Psychiat., 1941, 98, 83.Google Scholar
15. Fischer, R., et al., “Psychophysische korrelationene-VIII: Modellversuche zum Schizophrenieproblem, Lysergsaeure-diaethylamide und Mescalin”, Schweiz. Med. Wschr., 1951, 81, 817 and 837.Google Scholar
16. Hoch, P. H., et al., “Effects of mescaline and lysergic acid (d-LSD-25)”, Amer. J. Psychiat., 1952, 108, 579. February.Google Scholar
17. Mayer-Gross, W., et al., “Psychological and biochemical effects of lysergic acid diethylamide”, Nature, 1951, 168, 827. November.Google Scholar
18. Liddell, D. W., and Weil-Malherbe, , “The effects of methedrine and of lysergic acid diethylamide on mental processes and on the blood adrenaline level”, J. Neurol. Neurosurg. Psychiat., 1953, 16, 7. February.Google Scholar
19. Condrau, G., “Klinische Erfahrungen an Geisteskranken mit lysergsäure diäthylamid (Clinical experiences in mental patients with lysergic acid-diethylamide)”, Ejnar Munksgaard, Copenhagen, 1949, 24, 9.Google Scholar
20. Becker, A. M., “Zur Psychopathologie der Lysergsäure-diäthylamid-wirkung (On the psychopathology of the effect of lysergic acid diethylamide)”, Wien Ztschr. Nervenh., 1949, 2, 402.Google Scholar
21. Hyde, R. W., Private communication.Google Scholar
22. Hoch, P. H., et al., “Effect of drugs: theoretical considerations from a psychological viewpoint”, Amer. J. Psychiat., 1952, 108, 585.Google Scholar
23. Stefaniuk, W. B., Personal communication.Google Scholar
24. Fischer, R., “Factors involved in drug produced model psychoses”, J. Ment. Sci., 1954, 100, 623.Google Scholar
25. Fischer, R., and Agnew, N., “Competitive inhibition of drug-produced experimental psychoses”. Paper to be presented at the fall meeting of the Am. Chem. Soc. (Div. Biol. Chem.), N.Y., September, 1954.CrossRefGoogle Scholar
26. Elkes, J., Private communication.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.